Biotech News
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), will be presented in poster presentations at two international congresses in November and December 2026.
